-
-
-
Systematic review of the efficacy, effectiveness, and cost-effectiveness of stepped-care interventions for the prevention and treatment of problematic substance use J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-11-04 Ashleigh K. Morse, Jayden Sercombe, Mina Askovic, Alana Fisher, Christina Marel, Mary-Lou Chatterton, Frances Kay-Lambkin, Emma Barrett, Matthew Sunderland, Logan Harvey, Natalie Peach, Maree Teesson, Katherine L. Mills
Background Stepped-care is a commonly recommended and implemented care model across health care domains, including substance use. Despite their presumed efficient allocation of treatment resources, a current and robust evidence synthesis is needed on the efficacy, effectiveness and cost-effectiveness of stepped-care for substance use. Methods This systematic review analyzed articles describing evaluations
-
Factors associated with the adoption of evidence-based innovations by substance use disorder treatment organizations: A study of HIV testing J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-11-07 Lauren Broffman, Thomas D'Aunno, Ji E. Chang
Introduction Though prior research shows that a range of important regulatory, market, community, and organizational factors influence the adoption of evidence-based practices (EBPs) among health care organizations, we have little understanding of how these factors relate to each other. To address this gap, we test a conceptual model that emphasizes indirect, mediated effects among key factors related
-
National trends in buprenorphine prescribing before and during the COVID-19 pandemic J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-29 Mir M. Ali, Timothy B. Creedon, Laura Jacobus-Kantor, Tisamarie B. Sherry
Objective Recent studies have shown that early in the COVID-19 pandemic, rates of buprenorphine prescription dispensing for opioid use disorder (OUD) were relatively stable. However, whether that pattern continued later in the pandemic is unclear. This study examines the monthly rate of dispensed buprenorphine prescriptions during the early period and the later period of the pandemic. Methods The study
-
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-28 Colby J. Hyland, Michal J. McDowell, Paul A. Bain, Haiden A. Huskamp, Alisa B. Busch
Background Alcohol use disorder (AUD) represents the most prevalent addiction in the United States. Integration of AUD treatment in primary care settings would expand care access. The objective of this scoping review is to examine models of AUD treatment in primary care that include pharmacotherapy (acamprosate, disulfiram, naltrexone). Methods The team undertook a search across MEDLINE, PsycINFO,
-
Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-27 Rosanna Smart, Joo Yeon Kim, Susan Kennedy, Lu Tang, Lindsay Allen, Dushka Crane, Aimee Mack, Shamis Mohamoud, Nathan Pauly, Rosa Perez, Julie Donohue
Introduction The opioid crisis is transitioning to a polydrug crisis, and individuals with co-occurring substance use disorder (SUDs) often have unique clinical characteristics and contextual barriers that influence treatment needs, engagement in treatment, complexity of treatment planning, and treatment retention. Methods Using Medicaid data for 2017–2018 from four states participating in a distributed
-
Identifying factors that contribute to burnout and resilience among hospital-based addiction medicine providers: A qualitative study J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-26 Erin Bredenberg, Caroline Tietbohl, Ashley Dafoe, Lindsay Thurman, Susan Calcaterra
Introduction Inpatient Addiction Consultation Services (ACS) fill an important need by connecting hospitalized patients with substance use disorders with resources for treatment; however, providers of these services may be at risk for burnout. In this qualitative study, we aimed to identify factors associated with burnout and, conversely, resilience among multidisciplinary providers working on ACS
-
Digital interventions for opioid use disorder treatment: A systematic review of randomized controlled trials J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-31 Sarah Kanana Kiburi, Elizabeth Ngarachu, Andrew Tomita, Saeeda Paruk, Bonginkosi Chiliza
Introduction Opioid use disorders are associated with a high burden of disease and treatment gap. Digital interventions can be used to provide psycho-social treatment for opioid use disorders, as an alternative to or together with face-to-face interventions. This review aimed to assess the application and effectiveness of digital interventions to treat opioid use disorder globally. Methods The study
-
From there to here: A journey through substance use disorder, prison, and recovery J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-26 Patrick Franklin Hibbard
This narrative describes my experience with substance use disorder. It includes a trip through the criminal legal system, recovery, higher education, and a career in research. I convey key points from a history of using substances and committing crimes and how these created barriers to collegiate and professional aspirations, despite long-term recovery. The substance use services research field has
-
An intervention pilot to facilitate harm reduction service decentralization in Vietnam J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-29 Chunqing Lin, Li Li, Anh Tuan Le, Hoang My Lien Tran, Thanh Duyen Pham, Anh Tuan Nguyen
Introduction Harm reduction services, including methadone maintenance therapy (MMT), have been decentralized to Vietnam's community health care settings. This study aims to pilot test an intervention to facilitate decentralized harm reduction service delivery in Vietnam. Methods The research team conducted an intervention pilot between August 2020 and May 2021 with six community MMT distribution sites
-
A cohort study examining changes in treatment patterns for alcohol use disorder among commercially insured adults in the United States during the COVID-19 pandemic J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-28 Alisa B. Busch, Ateev Mehrotra, Shelly F. Greenfield, Lori Uscher-Pines, Sherri Rose, Haiden A. Huskamp
Introduction We know very little about how the pandemic impacted outpatient alcohol use disorder (AUD) care and the role of telemedicine. Methods Using OptumLabs® Data Warehouse de-identified administrative claims, we identified AUD cohorts in 2018 (N = 23,204) and 2019 (N = 23,445) and examined outpatient visits the following year, focusing on week 12, corresponding to the March 2020 US COVID-19 emergency
-
Housing and supportive services for substance use and self-efficacy among young mothers experiencing homelessness: A randomized controlled trial J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-27 Natasha Slesnick, Jing Zhang, Xin Feng, Allen Mallory, Jared Martin, Ruri Famelia, Brittany Brakenhoff, Tansel Yilmazer, Qiong Wu, Jodi Ford, Eugene Holowacz, Soren Jaderlund, Irene Hatsu, Ellison Luthy, Laura Chavez, Laura Walsh, Kelly Kelleher
Aims Homeless mothers with young children in their care contend with high rates of substance use and low self-efficacy. However, a limited number of studies have examined these outcomes associated with housing and supportive services. Design Participants were randomly assigned to: (1) housing + support services (n = 80), (2) housing-only (n = 80), or (3) services as usual (SAU) (n = 80) and were re-assessed
-
A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-26 Jawad M. Husain, Devin Cromartie, Emma Fitzelle-Jones, Annelise Brochier, Christina P.C. Borba, Cristina Montalvo
Introduction Clinical guidelines strongly recommend opioid agonist treatment (OAT) as first-line treatment for opioid use disorder (OUD). However, racial/ethnic minoritized patients are less likely to receive OAT compared to non-Hispanic White patients. Reasons for this treatment gap must be elucidated to address racial/ethnic disparities in OAT. Our objective is to evaluate perceptions of and barriers
-
Not in my treatment center: Leadership's perception of barriers to MOUD adoption J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-13 Rebecca E. Stewart, Nicholas C. Cardamone, David S. Mandell, Nayoung Kwon, Kyle M. Kampman, Hannah K. Knudsen, Christopher W. Tjoa, Steven C. Marcus
Introduction Despite their well-established effectiveness, medications for opioid use disorder (MOUD) are widely underutilized across the United States. In the context of a large publicly funded behavioral health system, we examined the relationship between a range of implementation barriers and a substance use disorder treatment agency's level of adoption of MOUD. Methods We surveyed leadership of
-
The role of the relational context and therapists' technical behaviors in brief motivational interviewing sessions for heavy alcohol consumption: Findings from a sample of Latinx adults J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-13 Molly Magill, Justin Walthers, Victor Figuereo, Liliana Torres, Zulma Montanez, Kristina Jackson, Suzanne M. Colby, Christina S. Lee
Introduction Motivational interviewing (MI) theory and process research highlights the role of therapist technical and relational behaviors in predicting client in-session statements for or against behavior change (i.e., change and sustain talk, respectively). These client statements, in turn, have been shown to predict intervention outcomes. The current study examines sequential associations between
-
Peer support to reduce readmission in Medicaid-enrolled adults with substance use disorder J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-13 Shari L. Hutchison, Kim L. MacDonald-Wilson, Irina Karpov, Amy D. Herschell, Tracy Carney
Introduction Peer support service in substance use disorder systems (PS SUD) is an optional supplement to treatment services for Medicaid-enrolled individuals across Pennsylvania. The value of PS SUD was defined through association with improved service utilization patterns. We examined service utilization in a subset of individuals receiving PS SUD following an acute service (hospitalization or withdrawal
-
Implementing clinical guidelines for co-occurring substance use and major mental disorders in Swedish forensic psychiatry: An exploratory, qualitative interview study with mental health care staff J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-12 J. Green, A.S. Lindqvist Bagge, S. Olausson, P. Andiné, M. Wallinius, M. Hildebrand Karlén
Introduction Patients with substance use disorders (SUD) and co-occurring mental disorders (COD) within forensic psychiatric care often suffer poor treatment outcomes and high rates of criminal recidivism, substance use, and psychiatric problems. This study aimed to describe the conditions for, and mental health care staff's experiences with, implementing integrated SUD-focused clinical guidelines
-
Service providers' perspectives on substance use and treatment needs among human trafficking survivors J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-05 Erica Koegler, Claire A. Wood, Sharon D. Johnson, Lilly Bahlinger
Introduction Understanding substance use and treatment needs for survivors of human trafficking remains an underdeveloped area in the field of substance use treatment. This study assessed the nature of substance use among survivors of all types of human trafficking and identified treatment barriers and needs, as reported by human trafficking service providers in one Midwest major metropolitan area
-
Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-04 Kevin A. Hallgren, James Darnton, Sean Soth, Kendra L. Blalock, Alyssa Michaels, Paul Grekin, Andrew J. Saxon, Steve Woolworth, Judith I. Tsui
Background Methadone is one of the most utilized treatments for opioid use disorder. However, requirements for observing methadone dosing can impose barriers to patients and increase risk for respiratory illness transmission (e.g., COVID-19). Video observation of methadone dosing at home could allow opioid treatment programs (OTPs) to offer more take-home doses while ensuring patient safety through
-
Associations between prescription and illicit stimulant and opioid use in the United States, 2015–2020 J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-30 Riley D. Shearer, Abenaa Jones, Benjamin A. Howell, Joel E. Segel, Tyler N.A. Winkelman
Introduction Overdose deaths involving opioids and stimulants continue to reach unprecedented levels in the United States. Although significant attention has been paid to the relationship between prescription and illicit opioid use, little work has focused on the association between prescription and illicit stimulant use. Thus, this study explores characteristics of those who use or misuse prescription
-
Substance use and criminogenic thinking: Longitudinal latent class analysis of veterans with criminal histories J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-01 Christine Timko, Noel Vest, Michael A. Cucciare, David Smelson, Daniel Blonigen
Introduction The objective of this study was to inform clinical practice by identifying distinct subgroups of US veterans with criminal histories in residential mental health treatment. The study characterized veteran patients on their alcohol and drug use and criminogenic thinking. We also examined predictors and outcomes of subgroup membership. Methods Participants were 341 veterans with a criminal
-
Longitudinal associations between pain and substance use disorder treatment outcomes J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-01 Erin Ferguson, Ben Lewis, Scott Teitelbaum, Gary Reisfield, Michael Robinson, Jeff Boissoneault
Introduction Pain is commonly reported among those in treatment for substance use disorders (SUD) and is associated with poorer SUD treatment outcomes. The current study examined the trajectory of pain over the course of SUD treatment and associations with substance use outcomes. Methods This observational study included adults seeking treatment for alcohol, cannabis, or opioid use disorders (N = 811)
-
OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-10-01 Theresa E. Tassey, Geoffrey E. Ott, Anika A.H. Alvanzo, Jessica M. Peirce, Denis Antoine, Megan E. Buresh
Introduction Rates of hospitalizations from medical complications of opioid use disorder (OUD) are rising and many of these patients require post–acute care at skilled nursing facilities (SNFs). However, access to medication for OUD (MOUD) at SNFs remains low and patients with OUD have high rates of patient-directed discharge (PDD) and hospital readmissions. Methods Opioid Use Disorder Medical Patient
-
Prescribing buprenorphine for opioid use disorder in primary care: A survey of French general practitioners in the Sentinelles network J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-30 Barbara Lépine, Marion Debin, Lise Dassieu, Laetitia Gimenez, Aurore Palmaro, Camille Ponté, Morgane Swital, Maryse Lapeyre-Mestre, Thierry Blanchon, Julie Dupouy
Introduction Although opioid substitution coverage in France is high and patient care with buprenorphine is mainly managed by general practitioners (GPs), buprenorphine sales have been decreasing since 2011, suggesting that French GPs are prescribing less buprenorphine. Yet this possible change in GP practices has not yet been investigated. This study aimed to examine primary care GPs' opinions about
-
Kindness, connection, and science J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-17 Kimberly C. Kirby
Abstract not available
-
Disease and decision J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-08 Kirsten E. Smith
At age 16, I injected morphine for the first time, and then started injecting heroin. By most standards, I was highly functioning, although I eventually became addicted. I was and remain socioeconomically privileged, but my relationship to heroin resulted in behaviors and consequences that I never could have conceived of, and which I sometimes strain to remember occurred. My life now is stable and
-
Opioid relapse and MOUD outcomes following civil commitment for opioid use J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-09 Jumi Hayaki, Haley Cinq-Mars, Paul P. Christopher, Bradley J. Anderson, Michael D. Stein
Introduction Opioid use disorder (OUD) continues to present a major public health problem in the United States. Civil commitment for substance use is one mandatory form of treatment for severe opioid use that has become increasingly available in recent years, but empirical data on this approach are lacking. This study examines clinical outcomes of civil commitment in a sample of adults with severe
-
Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-09 Wai Chung Tse, Nick Scott, Paul Dietze, Suzanne Nielsen
Aims Unsupervised injectable opioid agonist therapy (iOAT) may decrease the unmet treatment needs for people who inject opioids. We aimed to model whether unsupervised iOAT may be effective in reducing fatal and non–fatal overdose, and estimate the cost per life saved. Methods The study used a decision tree model based on Australian and international parameters for overdose risk in people who inject
-
The impact of race, gender, and heroin use on opioid addiction stigma J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-08 Kimberly Goodyear, Jasjit Ahluwalia, David Chavanne
Introduction Stigmatization of an opioid addiction acts as a barrier to those seeking substance use treatment. As opioid use and overdoses continue to rise and affect minority populations, understanding the impact that race and other identities have on stigma is pertinent. Methods This study aimed to examine the degree to which race and other identity markers (i.e., gender and type of opioid used)
-
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-09-01 Allison R. David, Carlos R. Sian, Christina M. Gebel, Benjamin P. Linas, Jeffrey H. Samet, Linda S. Sprague Martinez, Jordana Muroff, Judith A. Bernstein, Sabrina A. Assoumou
Introduction Access to and uptake of evidence-based treatment for substance use disorder, specifically opioid use disorder (OUD), are limited despite the high death toll from drug overdose in the United States in recent years. Patient perceived barriers to evidence-based treatment after completion of short-term inpatient medically managed withdrawal programs (detox) have not been well studied. The
-
Education and careers were our way out J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-08-31 Toby Lynch, Windia Rodriguez, David Eddie
Stigma thrives in vacuums of awareness where stereotypes are allowed to persist. When those of us with lived experience of addiction and addiction recovery stay in the shadows, we miss an opportunity to challenge a harmful narrative—that people with addiction are fundamentally different from other people and don't get better. Here, we three addiction treatment professionals share our lived experience
-
A randomized pilot trial of a mobile phone–based brief intervention with personalized feedback and interactive text messaging to reduce driving after cannabis use and riding with a cannabis impaired driver J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-08-19 Jenni B. Teeters, Nicole M. Armstrong, Shelby A. King, Sterling M. Hubbard
Introduction Driving after cannabis use (DACU) and riding with a cannabis-impaired driver (RWCD) are national public health concerns. Though driving impairments and increased crash risk make DACU and RWCD two of the riskiest cannabis-related behaviors, many continue to drive after use and ride with others who are under the influence and do not view DACU or RWCD as dangerous. The current study examined
-
Public injecting and its association with mental health and other drug-related outcomes among people who inject drugs in Iran J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-08-19 Mehrdad Khezri, Fatemeh Tavakoli, Mohammad Karamouzian, Hamid Sharifi, Nima Ghalehkhani, Ghazal Mousavian, Soheil Mehmandoost, Matin Bazargani, Ali Mohammad Hosseinpour, Marzieh Mahboubi, Stefan Baral, Mostafa Shokoohi
Background Injecting in public places may increase the risk of drug and health-related harms among people who inject drugs (PWID). We examined the prevalence of public injecting and associations with non–fatal overdose, needle/syringe sharing, sexual health, and mental health among PWID in Iran. Methods Using respondent-driven sampling, we recruited 2684 PWID from 11 major cities between July 2019
-
Patterns and contexts of polysubstance use among young and older adults who are involved in the criminal legal system and use opioids: A mixed methods study J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-08-13 Corianna E. Sichel, Daniel Winetsky, Stephanie Campos, Megan A. O'Grady, Susan Tross, Jane Kim, Alwyn Cohall, Renee Cohall, Katherine S. Elkington
Introduction Opioid prevention and treatment programs tailored to young adults involved in the criminal legal system are rare. We examined profiles of polysubstance use among younger and older adults involved in the criminal legal system who use opioids, and explored their experiences and motivations related to substance use. Information gleaned can inform the adaptation of existing programs and the
-
Influences of poly-victimization on adolescents' pre-treatment cognitive motivations and post-treatment outcomes J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-08-13 Nina C. Christie, Graham DiGuiseppi, Sheila Pakdaman, Daniel S. Lee, Duyen Pham, Shaddy K. Saba, Jordan P. Davis
Introduction Substance use treatment outcomes are challenging to predict: myriad potentially relevant factors influence outcomes, including age, sex, motivations, and history of victimization. Methods The current study seeks to assess these factors in adolescents through an evaluation of the relationship between distinct victimization profiles, sex, and cognitive factors related to substance use treatment
-
Recidivism prevention for impaired driving: Longitudinal 5-year outcomes from Quebec's severity-based intervention assignment program J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-08-06 Thomas G. Brown, Nathaniel Moxley-Kelly, Marie Claude Ouimet
Introduction Driving while impaired by alcohol (DWI) is a persistent problem. Tailoring intervention modality to client risk and needs (i.e., risk/needs) is posited to both reduce recidivism more efficiently than uniform approaches and circumvent overtreatment or undertreatment. DWI drivers in Quebec must participate in a severity-based intervention assignment program to be relicensed, but like most
-
Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-29 Kate LaForge, Erin Stack, Sarah Shin, Justine Pope, Jessica E. Larsen, Gillian Leichtling, Judith M. Leahy, Andrew Seaman, Dan Hoover, Mikaela Byers, Caiti Barrie, Laura Chisholm, P. Todd Korthuis
-
Drug court utilization of medications for opioid use disorder in high opioid mortality communities J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-29 Douglas B. Marlowe, David S. Theiss, Erika M. Ostlie, John Carnevale
Introduction A 2012 national survey found low utilization of medication for opioid use disorder (MOUD) in US drug courts. This study provides an update on MOUD policies and practices among drug courts in communities that the opioid epidemic has substantially impacted. Methods The study surveyed adult drug courts (N = 169, 80 % response rate) in US counties with high opioid mortality rates or numbers
-
Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-29 Sarah E. Wakeman, Sydney McGovern, Laura Kehoe, Martha T. Kane, Elizabeth A. Powell, Sarah K. Casey, Giovanie M. Yacorps, Jasmine R. Irvin, Windia Rodriguez, Susan Regan
Introduction People with substance user disorder (SUD) have frequent intersections with the health care system; however, engagement and retention in SUD care remain low, particularly for marginalized populations. Low-threshold treatment models that aim to eliminate barriers to care are one proposed intervention to increase access and equity in SUD treatment. Methods This is a retrospective, cohort
-
Can nicotine replacement therapy be personalized? A statistical learning analysis J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-29 Scott Veldhuizen, Laurie Zawertailo, Sarwar Hussain, Sabrina Voci, Peter Selby
Background Technology has made automated care personalization practical, but useful personalization requires information about systematic differences between individuals in the effectiveness of different interventions. Here, we used observational data to search for differences in smoking cessation treatment outcomes associated with interactions between participant characteristics and different types
-
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-30 Audun J. Lier, Nikhil Seval, Brent Vander Wyk, Angela Di Paola, Sandra A. Springer
Introduction Opioid use disorder (OUD) and injection drug use (IDU) place justice-involved individuals at increased risk for acquiring or transmitting HIV or hepatitis C virus (HCV). Methadone and buprenorphine have been associated with reduced opioid IDU; however, the effect of extended-release naltrexone (XR-NTX) on this behavior is incompletely studied. Methods This study examined injection opioid
-
Use of long-acting injectable buprenorphine in the correctional setting J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-29 Rosemarie A. Martin, Justin Berk, Josiah D. Rich, Augustine Kang, John Fritsche, Jennifer G. Clarke
Background As overdoses due to opioids rise, medications for opioid use disorder (MOUD) continue to be underemployed, resulting in limited access to potentially life-saving treatment. Substance use disorders are prevalent in individuals who are incarcerated, and these individuals are at increased risk for death postrelease due to overdose. Few jails and prisons offer MOUD and most limit access. Extended-release
-
A Call for Kindness, Connection, and Science J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-16 Barbara Straus Lodge
Introduction This personal narrative describes our family's struggle with my adult son's substance use disorder (SUD). Years of traditional tough love treatment programs worsened his SUD and our relationship. When he experienced drug induced psychosis and was hospitalized, I realized I needed to change my approach and understand his behaviors. Methods I reached out to the recovery community and spoke
-
Emergency department interventions for opioid use disorder: A synthesis of emerging models J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-11 Cindy Parks Thomas, Maureen T. Stewart, Cynthia Tschampl, Kumba Sennaar, Daniel Schwartz, Judith Dey
Introduction Opioid overdose deaths are increasing, and improving access to evidence-based treatment is necessary. Emergency department (ED) initiation of treatment for opioid use disorder (OUD) via medications and referral to treatment is one approach that leverages a critical health care entry point for individuals with OUD. Efforts to engage patients in treatment through the ED are growing, but
-
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-12 John Will, Marce Abare, Mollie Olson, Alexander Chyorny, Emilee Wilhelm-Leen
Introduction Individuals with opioid use disorder (OUD) are highly represented among the incarcerated population and are frequent utilizers of the emergency department (ED). Medications for opioid use disorder (MOUD) are a recognized treatment option for individuals with OUD. Although the field recognizes the benefits of MOUD, we know little about what mitigating effects MOUD offered in jail might
-
Improving geographic access to methadone clinics J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-11 Anthony Bonifonte, Erin Garcia
Introduction Opioid misuse is a nationwide public health crisis. Methadone treatment is proven to be highly successful in preventing opioid use disorder, reducing the use of illicit drugs, and preventing overdoses. Clients acquire methadone daily from clinics, making geographic access crucial for the initiation of and adherence to treatment. Methods This work estimates unsatisfied methadone demand
-
Associations of tobacco cigarette use and dependence with substance use disorder treatment completion by sex/gender and race/ethnicity J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-03 Jung-Yun Min, Jacob Levin, Andrea H. Weinberger
Introduction Individuals with substance use disorders (SUD) are approximately five times more likely to smoke cigarettes than the general population. Individuals who smoke cigarettes have greater odds of SUD relapse compared to individuals who do not smoke cigarettes, but we know little about how cigarette use is related to SUD treatment completion overall by sex/gender or race/ethnicity. Methods This
-
Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-07-02 Ali Jalali, Philip J. Jeng, Daniel Polsky, Sabrina Poole, Yi-Chien Ku, George E. Woody, Sean M. Murphy
Introduction Opioid use disorder (OUD) is highly prevalent among incarcerated populations, and the risk of fatal overdose following release from prison is substantial. Despite efficacy, few correctional facilities provide evidence-based addiction treatment. Extended-release injectable naltrexone (XR-NTX) administered prior to release from incarceration may improve health and economic outcomes. Methods
-
Client attitudes toward virtual treatment court J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-28 Bradley Ray, Tara Kunkel, Kristina Bryant, Bethany Hedden, Barbara Andraka-Christou, Meghan O'Neil, Philip Huynh
Introduction As a response to the COVID-19 pandemic, many treatment courts shifted to offering teleservices. We sought to examine the barriers that clients faced when transitioning to virtual court and treatment, and how this transition impacted their perceptions of the treatment court experience. Methods The National Center for State Courts administered an online survey between January 1, 2021, and
-
Adapting methadone inductions to the fentanyl era J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-27 Megan Buresh, Shadi Nahvi, Scott Steiger, Zoe M. Weinstein
Since 2013, fentanyl and fentanyl analogs, which are significantly more potent than heroin, have been increasingly prevalent in the opioid drug supply. A need exists to adapt methadone dosing from opioid treatment programs (OTPs) in this era. Current methadone protocols at many clinics in the United States are based on expert consensus documents that were created prior to the introduction of fentanyl
-
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-22 Amanda M. Bunting, Noa Krawczyk, Tse-Hwei Choo, Martina Pavlicova, Jennifer McNeely, Babak Tofighi, John Rotrosen, Edward Nunes, Joshua D. Lee
Objective Polysubstance use may complicate treatment outcomes for individuals who use opioids. This research aimed to examine the prevalence of polysubstance use in an opioid use disorder treatment trial population and polysubstance use's association with opioid relapse and craving. Methods This study is a secondary data analysis of individuals with opioid use disorder who received at least one dose
-
Utility of interactive voice response self-monitoring in stabilizing initial change during natural recovery attempts among persons with alcohol use disorder J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-22 JeeWon Cheong, Jalie A. Tucker
Background Providing extensive low threshold, low intensity interventions during self-initiated recovery attempts may help to stabilize initial change during early recovery when relapse risk is high. This study provided untreated persons with alcohol use disorder (AUD) daily access to an interactive voice response (IVR) self-monitoring system during the early months of a natural recovery attempt to
-
Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-16 Margaret M. Paschen-Wolff, Rachel Velasquez, Nicole Aydinoglo, Aimee N.C. Campbell
Introduction Lesbian, gay, bisexual, transgender, and queer (LGBTQ) populations experience opioid-related disparities compared to heterosexual and cisgender populations. LGBTQ-specific services are needed within opioid use disorder (OUD) treatment settings to minimize treatment barriers; research on the availability and accessibility of such services is limited. The purpose of the current study was
-
Using structured implementation interventions to improve referral to substance use treatment among justice-involved youth: Findings from a multisite cluster randomized trial J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-19 Steven Belenko, Richard Dembo, Danica K. Knight, Katherine S. Elkington, Gail A. Wasserman, Angela A. Robertson, Wayne N. Welsh, James Schmeidler, George W. Joe, Tisha Wiley
Introduction Youth involved in the justice system have high rates of alcohol and other drug use, but limited treatment engagement. JJ-TRIALS tested implementation activities with community supervision (CS) and behavioral health (BH) agencies to improve screening, identification of substance use service need, referral, and treatment initiation and engagement, guided by the BH Services Cascade and EPIS
-
Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-16 Lewei (Allison) Lin, Victoria D. Powell, Colin Macleod, Amy S.B. Bohnert, Pooja Lagisetty
Background This study examined factors associated with treatment recommendations for patients with a new diagnosis of opioid use disorder (OUD), comparing recommendations for patients with clear signs of OUD versus those with lower likelihood of OUD. Methods The study conducted a retrospective medical chart review in a randomly selected national sample of 520 Veteran Health Administration patients
-
A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients' sexual risk behavior J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-16 Mary A. Hatch, Elizabeth A. Wells, Tatiana Masters, Blair Beadnell, Robin Harwick, Lynette Wright, Michelle Peavy, Esther Ricardo-Bulis, Katerina Wiest, Carrie Shriver, John S. Baer
Introduction High risk sex—such as sex with multiple partners, condomless sex, or transactional or commercial sex—is a risk factor in individuals with substance use disorders (SUDs). SUD treatment can reduce sexual risk behavior, but interventions to reduce such behavior in this context have not been consistently effective. This study sought to determine if the impact of treatment on sexual risk behavior
-
Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-16 William N. Dowd, Daniel H. Barch, Julie H. Seibert, Tami L. Mark
Objective Medication for opioid use disorder (MOUD) is effective but underused. Measuring the percentage of a provider's patients with an opioid use disorder (OUD) who receive MOUD may drive quality improvement and stimulate greater use of medications. This study introduces and tests a provider-level measure of MOUD receipt. Methods The study used claims and enrollment data from 32 states in the 2014
-
Using machine learning to examine predictors of treatment goal change among individuals seeking treatment for alcohol use disorder J. Subst. Abus. Treat. (IF 3.7) Pub Date : 2022-06-16 Frank J. Schwebel, Noah N. Emery, Rory A. Pfund, Matthew R. Pearson, Katie Witkiewitz
Introduction The goals of individuals seeking treatment for alcohol use disorder (AUD) are typically quantified as abstinent or nonabstinent (e.g., moderate drinking) goals. However, treatment goals can vary over time and be influenced by life circumstances. This study aims to identify predictors of treatment goal change and direction of change from baseline to six-month follow-up among individuals
-